The Patient Partnership Index is run by OVID Health the leading global agency in patient advocacy & engagement.

In 2020 we launched the Patient Partnership Index (PPI).

The PPI has since grown into a global initiative to enable patient groups, pharmaceutical and biotech companies to showcase, benchmark and evaluate the quality of their patient partnerships.

Its aim is to celebrate as many partnerships that meet the mark as possible, while sharing best practice and raising the bar across the industry. 

Now in its fourth year, the PPI evaluates and commends patient-pharmaceutical initiatives across communications, advocacy, clinical trials and market access.

Partnering with patients and patient organisations has become second nature to biopharmaceutical companies in the past five years. The Index reflects this focus & enables pharmaceutical companies to demonstrate their commitment to patient centricity and showcase the work they have carried out.

Jenny Ousbey, CEO & Founder, OVID Health

The Index is the culmination of thoughtful discussion and research, with a sole goal in mind: to improve patient outcomes through high quality patient-pharmaceutical partnerships in communications, advocacy, medical affairs and market access.

The concept of patient centricity is mainstream now in research and development, including in clinical trials and patient support programmes. But the Index looks beyond ‘centricity’ in R&D and into partnerships of equals for three reasons: one, because ‘centricity’ can be passive; two, it is traditionally tied to R&D; and three, because top quality communications between companies and patient groups is about collaborating as equals.

“We are delighted our partnership with Kyowa Kirin has been recognised in this way. CTCL is a rare type of skin lymphoma that requires input from a multidisciplinary team of healthcare professionals from a number of specialisms. The aim of developing a treatment centre map, in conjunction with Kyowa Kirin, was to inform healthcare professionals on where specialist treatment for CTCL is available, and to support their patients with one of the many challenges that a diagnosis of a rare type of cancer can bring.”

Dallas Pounds, Director of services, Lymphoma action